Canada: B.C. Court Confirms Plaintiffs Must Provide Workable Causation Methodology To Certify Product Liability Class Proceedings

In Charlton v. Abbott Laboratories, Ltd., 2015 BCCA 26 (Charlton), the British Columbia Court of Appeal clarified the evidentiary threshold plaintiffs must satisfy at the certification stage in the context of product liability class actions. In particular, the Court confirmed that plaintiffs alleging that a product causes adverse effects or injury must adduce evidence of a workable methodology to demonstrate that the product in question was capable of causing adverse effects on a class-wide basis. In so ruling, the Court reiterated the principles articulated by the Supreme Court in the 2013 "indirect purchaser trilogy," and affirmed their application to the product liability context. Ultimately, the plaintiffs in Charlton failed to adduce sufficient evidence of general causation, which proved fatal to the certification of the action.

Background

In 2011, a class action was commenced against Abbott Laboratories, Ltd. (Abbott) and Apotex, Inc. (Apotex) on behalf of all individuals in Canada who were prescribed a drug containing sibutramine, on the basis that ingestion of sibutramine allegedly caused or contributed to adverse cardiovascular health, including heart attacks, strokes, increased blood pressure, increased heart rate and irregular heartbeat. The plaintiffs pleaded various causes of action, including negligence, failure to warn and breaches of the B.C. Business Practices and Consumer Protection Act and the Competition Act, in addition to seeking damages pursuant to the doctrine of waiver of tort.

Notably, some of the members of the class reported suffering from cardiovascular events like heart attacks or strokes after being prescribed sibutramine, while others had not. Furthermore, it was unclear from the evidence how many class members (if any) had a pre-existing history of cardiovascular illness.

Expert Evidence at Certification

The plaintiffs filed two medical expert reports in support of their application for certification, and the defendants filed two responding expert reports. After considering the expert evidence as whole, the Court of Appeal summarized the evidence as follows:

  • There was some evidence of increased risk for cardiovascular events in individuals with pre-existing heart problems.
  • The Canadian product monograph cautioned against prescribing sibutramine to patients with a history of cardiovascular disease.
  • There was no evidence presented to suggest that the drugs in question had in fact been prescribed to individuals with pre-existing conditions.
  • The extent of the risk for individuals with no history of cardiovascular disease had not been studied, and the statistical evidence that was available did not demonstrate a measurable increase in the risk for patients with no history of cardiovascular disease.

The B.C. Supreme Court's Decision on Certification

The certification judge found the claim met the test for certification in all respects and certified the class, which was defined as "[a]ll persons in Canada who were prescribed and ingested [sibutramine] ... ."

Among the various common issues certified by the certification judge was the issue of whether sibutramine causes or contributes to heart attacks, strokes and irregular heartbeat in relation to all Canadian patients who were prescribed and ingested drugs containing sibutramine, whether or not they had a pre-existing cardiovascular condition.

The appellants appealed the certification decision, arguing that the certification judge erred in principle by certifying the proceedings. The appellants focused their argument on the asserted failure of the plaintiffs to lead evidence of a methodology for establishing general causation on a class-wide basis.

B.C. Court of Appeal Overturns Certification

Relying on the Supreme Court of Canada's 2013 trilogy of cases in the indirect purchaser context,1 the B.C. Court of Appeal reiterated the principle that a class action should not be certified where a plaintiff fails to adduce some evidentiary basis for a methodology that could be used by the Court to answer the common questions. In this regard, the Court observed that the question of class-wide general causation should not be certified as a common issue without evidence of a methodology to prove such causation in respect of the class as a whole. In so commenting, the Court drew a distinction between certain prior pharmaceutical class actions in which causation had been held to be sufficiently established on the basis of evidence of a general increase in risk to the class caused by using the drug in question and the case before it, where no such generalized risk data was available.

The Court ultimately concluded that the lack of a methodology for demonstrating general causation was an insurmountable evidentiary hurdle:

[t]here was no evidence of a methodology for establishing that the class as a whole, as opposed to those who were wrongly prescribed sibutramine despite a history of disease, was affected or put at risk by its use of sibutramine. ...

While there is no dispute that those with pre-existing cardiopulmonary disease are at a statistically increased risk of adverse cardiac events, this is not a case where the experts disagree on the extent of the risk, but rather, a case where the experts are uncertain whether there is a risk to the class as a whole and cannot describe a methodology for addressing that question.

The remaining common issues hinged upon a finding of general causation on a class-wide basis. Accordingly, absent a workable methodology for addressing causation, the Court concluded that certification should not have been granted and set aside the certification order of the trial judge.

Notably, in denying certification, the B.C. Court of Appeal also harmonized an apparent inconsistency between the trial judge's decision in Charlton and a parallel proceeding in Québec in which certification had been denied (though admittedly in the context of a different legal regime). In particular, the Québec Superior Court was presented with a similar evidentiary record to that in Charlton, and held in a decision released in 2012 that the evidence put forward by the plaintiffs in that case was insufficient to meet the test for class action authorization pursuant to section 1003 of the Québec Code of Civil Procedure.

Implications: A Stricter Approach to Certification?

The appellate decision in Charlton represents a clear affirmation of the recent judicial statements to the effect that class action plaintiffs bear the burden of establishing causation on a class-wide basis. In particular, the case illustrates the fact that causation cannot simply be presumed, nor is it sufficient for plaintiffs to simply argue that a product could – in the abstract – cause injury to certain consumers. Rather, the plaintiffs must adduce some evidence – or at least a workable methodology at the certification stage – in order to satisfy the courts that some manner of class-wide conclusions regarding causation could reasonably be drawn.

Moreover, the case is also reflective of the increased willingness on the part of the courts to intervene at the certification stage where the underlying merits of the proceedings are somehow problematic. In particular, as discussed in a previous Osler Update, the courts appear to have moved away from a rigid application of the certification criteria to a broader consideration of the proceedings as a whole. Although the certification test is not intended to be a test of the merits of the action, the decision in Charlton nonetheless demonstrates the crucial importance of the evidentiary record, even at the certification stage. In the wake of the Supreme Court of Canada's reaffirmation that certification should serve as a "meaningful screening device"2, courts are now carefully considering the inter-relationship between the definition of the class, the common issues and the available evidence to determine not only whether the certification test has been met, but also whether the matter should be allowed to proceed more generally.

Footnotes

1. Pro-Sys Consultants Ltd. v. Microsoft Corporation, 2013 SCC 57 [Pro-Sys], Sun-Rype Products Limited v. Archer Daniels Midland Company, 2013 SCC 58, and Infineon Technologies AG v. Option consommateurs, 2013 SCC 59.

2. Pro-Sys, supra at para. 103.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions